445 Results for "

disease (AD)

" in MedChemExpress (MCE) Product Catalog:
Products (445)

445 Results for "disease (AD)" in MCE Product Catalog:

101
101 Publications Verification
Cat. No.: HY-114153
CAS No.: 1303420-67-8
Purity:  99.79%
Target:  

c-Fms

PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 is an ideal choose for microglia function research in healthy or diseased states. PLX5622 has been verified by MedChemExpress, which demonstrates desirable microglia depletion efficiency in mice. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-50682
CAS No.: 603148-36-3
Synonyms: TTP488; PF-04494700
Target:  

Amyloid-β

Research Areas:  

Neurological Disease Cancer

Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-A0009
CAS No.: 1953-04-4
Synonyms: Galantamine hydrobromide
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-N0028
CAS No.: 79916-77-1
Forsythiaside A is an orally active phenylethanoid glycoside isolated from the dried fruits of Forsythia suspensa. Forsythiaside A is also an inhibitor of COX-2 and has anti-inflammatory, antioxidant and neuroprotective effects. Forsythiaside A prevents neuroinflammation and apoptosis caused by Aβ25-35 damage and may be used in Alzheimer's disease (AD) research. Forsythiaside A also activates the Nrf2/HO-1 signaling pathway and inhibits OVA-induced asthma in mice. Forsythiaside A inhibits the interaction between KLRB1 and CLEC2D .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-19369
CAS No.: 292632-98-5
Synonyms: L-685,458
Target:  

γ-secretase Apoptosis

Research Areas:  

Neurological Disease Cancer

L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC50s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-113354
CAS No.: 584-85-0
Purity:  99.85%
Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine has blood-brain barrier permeability, and improves memory functions in Alzheimer's disease (AD)-model mice .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P0198
CAS No.: 90880-35-6
Synonyms: Neuropeptide Y (29-64), amide
Neuropeptide Y (human,rat,mouse) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P0198A
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0710
CAS No.: 473-08-5
Synonyms: α-Cyperone; (+)-α-Cyperone
alpha-Cyperone (α-Cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1, resulting in reduction of inflammation, which would be highly beneficial for treatment of inflammatory diseases such as AD.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0124
CAS No.: 68291-97-4
Synonyms: AD 810; CI 912
Research Areas:  

Neurological Disease

Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-D0186
CAS No.: 951-78-0
2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P7531
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: APOE; Apolipoprotein E3; Prev. AD2; APO-E; Alzheimer disease 2 (APOE*E4-Associated, Late Onset); ApoE4; Apolipoprotein E Isoform 4; Apo-E; Apolipoprotein E Isoform 5; LPG; Apolipoprotein E Isoform 2; Apolipoprotein E; LDLCQ5
Species:  
Human
Source:  
HEK293
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117049
CAS No.: 1112978-84-3
Purity:  98.70%
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and CDC-like kinases (CLKs). Leucettine L41 can also inhibit GSK-3 singnaling. Leucettine L41 can inhibit cell apoptosis and ROS production. Leucettine L41 can promote β-cell cell cycle progression, cell proliferation and increase insulin secretion. Leucettine L41 can be used for the researches of neurological disease and metabolic disease, such as Alzheimer’s disease (AD) and diabetes .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P70577
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuclein; Synuclein, Alpha (Non A4 Component Of Amyloid Precursor); Α-Synuclein; Synuclein Alpha; Non A4 Component Of Amyloid Precursor
Species:  
Human
Source:  
E. coli
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10863
CAS No.: 94421-68-8
Purity:  ≥98.0%
Synonyms: AEA; Arachidonoyl ethanolamide
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-Y0808
CAS No.: 106-65-0
Dimethyl succinate is an orally active cell permeable succinate analogue. Dimethyl succinate can disrupt the TCA cycle by elevating intracellular succinate levels, leading to reduced protein synthesis and impairs myogenic differentiation. Dimethyl succinate can induce apoptosis. Dimethyl succinate can decrease maximal cellular respiration and reserve capacity. Dimethyl succinate can rescue synapse loss in AD. Dimethyl succinate can be used for the researches of metabolic and neurological disease [1][2].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12879
CAS No.: 686772-17-8
Purity:  99.81%
IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132831
CAS No.: 2260969-36-4
Purity:  99.46%
Synonyms: Somalix; RO-7486967; IZD334
Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109055
CAS No.: 1388651-30-6
Purity:  99.82%
Synonyms: E2609
Target:  

Beta-secretase

Research Areas:  

Neurological Disease

Elenbecestat (E2609) is a potent, orally bioavailable and BBB-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-163885
CAS No.: 1262287-23-9
SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice .
loading...
    loading...